Benign Prostatic Hyperplasia

Robert C Langan

doi:10.1016/j.pop.2019.02.003

Benign Prostatic Hyperplasia

Prim Care. 2019 Jun;46(2):223-232. doi: 10.1016/j.pop.2019.02.003. Epub 2019 Apr 1.

Author

Robert C Langan¹

Affiliation

¹ St. Luke's Family Medicine Residency, Sacred Heart Campus, 450 Chew Street, Suite 101, Allentown, PA 18102, USA; Department of Family and Community Medicine, Temple University School of Medicine, Philadelphia, PA, USA. Electronic address: Robert.Langan@sluhn.org.

PMID: 31030823
DOI: 10.1016/j.pop.2019.02.003

Abstract

Benign prostatic hyperplasia (BPH) is a common condition in aging men that is frequently associated with troublesome lower urinary tract symptoms (LUTS). The American Urologic Association Symptom Index is a validated, self-administered tool that is used to diagnose LUTS, guide initial treatment, and assess treatment response. Watchful waiting is an option for men with mild symptoms. Pharmacologic treatment includes alpha-adrenergic blockers and 5-alpha reductase inhibitors. There is no evidence to support the use of herbal supplements in the treatment of LUTS. Surgical therapy is effective and indicated for men with complications from BPH or who fail medical therapy.

Keywords: 5-alpha reductase inhibitors; Alpha-adrenergic blockers; Benign prostatic hyperplasia; Lower urinary tract symptoms; Transurethral resection of the prostate.

Publication types

Review

MeSH terms

5-alpha Reductase Inhibitors / therapeutic use*
Adrenergic alpha-Antagonists / therapeutic use*
Humans
Lower Urinary Tract Symptoms / etiology
Male
Prostatic Hyperplasia / complications
Prostatic Hyperplasia / diagnosis*
Prostatic Hyperplasia / drug therapy
Prostatic Hyperplasia / therapy

Substances

5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists